This study examines the clinical and genetic factors related to Turner syndrome, a disorder
of the sex chromosomes. Humans usually have 23 pairs of chromosomes-thin strands of DNA-in
the nucleus of every cell, which contain genes that determine our hereditary makeup. One
pair of chromosomes is the sex chromosomes, designated X and Y. Females usually have two X
chromosomes; however, patients with Turner syndrome have only a single X chromosome or one
normal and one defective X or Y chromosome. This abnormality can cause medical problems such
as short stature, premature ovarian failure and heart or kidney defects. Individuals with
Turner syndrome have an increased risk of thyroid disorders, high blood pressure, diabetes
mellitus, abnormal liver function, hearing loss and osteoporosis. This study will try to
identify the genes responsible for the specific medical problems associated with the
disorder.
Females 10 years of age and older with X chromosome defects may be eligible for this 3- to
5- day inpatient study at the National Institutes of Health Clinical Center in Bethesda,
Maryland. Participants will have a physical examination, body measurements (height, weight,
hip and waist) and blood drawn for clinical and research purposes.
Participants will have a comprehensive cardiovascular evaluation, including an
electrocardiogram (ECG), 24 hour blood pressure monitoring, magnetic resonance imaging (MRI)
of the heart and aorta, ultrasound imaging of the heart (cardiac echo) and expert
consultation with the NIH Cardiology Service. Women 35 years of age and older may have a
computerized tomography (CT) scan of the coronary arteries to investigate possible blockage
of the heart blood supply.
Risk for diabetes is investigated by studies of the body fat content and an oral glucose
tolerance test. The risk for coronary artery disease is assessed by measurement of
cholesterol and other known risk factors in the blood. Thyroid function and presence of
antibodies to the thyroid gland are also evaluated by blood tests.
Liver function is tested by measurement of products of liver metabolism in the blood and by
a liver ultrasound. Ovary function is investigated by blood tests of estrogen and FSH levels
and pelvic untrasound which visualizes the uterus.
Bone structure and strength are evaluated by routine X-rays of the wrists and spine, and
DEXA scan (a type of X-ray study that measures body fat, muscle and bone thickness). Adults
will also have bone density of the spine and abdominal fat content measured by CT, which is
more accurate than DEXA. Vitamin D levels are measured in blood tests.These are state of the
art diagnostic tests which may uncover unsuspected anatomic problems such as abnormalities
of the aorta or aortic valve which have serious clinical implications and would indicate the
need for close medical follow-up, as well as uncover potential risk for development of
diabetes or osteoporosis in the future, which would also indicate the need for changes in
lifestyle or medical management. Study participants are invited to return for re-evaluation
at 1-3 year intervals. A major goal of follow-up visits is to determine whether there is
any enlargement of aortic diameter or impairment of cardiac function over time.
Some patients may be asked to undergo a skin biopsy (removal of a small sample of skin
tissue) to obtain more information about genetic make-up of cells. Parents of patients may
be contacted (with the patient's permission) to provide a blood or saliva sample for genetic
study to help understand how and why certain traits of Turner syndrome are expressed.
Study Type: Treatment
| Condition |
Treatment |
Phase |
Turner's Syndrome
|
None
|
N/A
|
Study Design:N/A
Official Title: Turner Syndrome: Genotype and Phenotype
Further Study Details:
Expected Total Enrollment:
Study Dates:September 2000 -
Turner Syndrome (TS) is a sporadic disorder affecting approximately 1/2500 live female
births. It is caused by the absence of all or significant parts of one sex-chromosome.
Major developmental consequences include severe short stature, ovarian failure and
distinctive cognitive and behavioral traits, with renal and cardiovascular defects affecting
a minority. Adults with TS have excessive rates of osteoporosis, hypertension and diabetes
mellitus and experience morbidity and mortality several-fold higher than the general
population. Many of the problems of TS result from haplo-insufficiency for X-chromosome
encoded genes, most of which remain unknown. Previous studies attempting to correlate
genotype with phenotype in TS have been limited due to small numbers of subjects, limited
genetic methodology and incomplete phenotypic characterization. This study aims to
correlate TS phenotypes and genotypes using advanced clinical and genetic diagnostic
methodologies, with the goal of identifying X-chromosome genes and epigenetic mechanisms
causing the different features of TS. For TS subjects with a 45X genotype, the parental
origin of the single normal X-chromosome will be traced to identify genomically imprinted
features of the disorder. X chromosomal structural defects will be analyzed using
high-resolution physical mapping in relation to emerging sequence data from the Human Genome
Project. The elucidation of genetic mechanisms in TS will help improve the diagnosis and
treatment of girls and women with this disorder and will further our understanding of gene
dosage effects in general.
Ages Eligible for Study- Min: 10 Years Max: N/A
Gender: Both
Criteria
INCLUSION CRITERIAfor TS Subjects:
Phenotypic females greater than or equal to 10 years of age
Evidence of X-chromosomal abnormality
Those with a karyotype of 45X/46XX must have at least 80% 45X lymphocytes.
EXCLUSION CRITERIAfor TS Subjects:
Co-existing autosomal defects
Pregnancy
INCLUSION CRITERIAfor the Parents of TS Subjects (for DNA only):
Biological parent of a TS subject
Willingness to participate
EXCLUSION CRITERIAfor the Parents of TS Subjects (for DNA only):
None
Please refer to this study by ClinicalTrials.gov identifier: NCT00006334
National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda, Maryland 20892
Record Last Reviewed:April 2010
Last Updated:July 7, 2010
Record First Recieved:October 4, 2000
ClinicalTrials.gov Identifier:NCT00006334
Health Authority: United States Food and Drug Administration
Information obtained from ClinicalTrials.gov on September 02, 2010